

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Temasek Holdings (Private) Ltd</u> <hr/> (Last) (First) (Middle) 60B ORCHARD ROAD #06-18 TOWER 2 THE ATRIUM@ORCHARD <hr/> (Street) SINGAPORE U0 238891 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 05/05/2016	3. Issuer Name and Ticker or Trading Symbol <u>Intellia Therapeutics, Inc. [ NTLA ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Series B Preferred Stock	(1)	(1)	Common Stock 490,527	(1)	I	Held by TLS Beta Pte. Ltd. <sup>(2)</sup>

1. Name and Address of Reporting Person* <u>Temasek Holdings (Private) Ltd</u> <hr/> (Last) (First) (Middle) 60B ORCHARD ROAD #06-18 TOWER 2 THE ATRIUM@ORCHARD <hr/> (Street) SINGAPORE U0 238891 <hr/> (City) (State) (Zip)
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1. Name and Address of Reporting Person* <u>Fullerton Management Pte Ltd</u> <hr/> (Last) (First) (Middle) 60B ORCHARD ROAD #06-18 TOWER 2 THE ATRIUM@ORCHARD <hr/> (Street) SINGAPORE U0 238891 <hr/> (City) (State) (Zip)
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1. Name and Address of Reporting Person*		
<a href="#">Temasek Life Sciences Private Ltd</a>		
(Last)	(First)	(Middle)
60B ORCHARD ROAD #06-18 TOWER 2 THE ATRIUM@ORCHARD		
(Street)		
SINGAPORE	U0	238891
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
<a href="#">TLS Beta Pte. Ltd.</a>		
(Last)	(First)	(Middle)
60B ORCHARD ROAD #06-18 TOWER 2 THE ATRIUM@ORCHARD		
(Street)		
SINGAPORE	U0	238891
(City) (State) (Zip)		

**Explanation of Responses:**

- Each share of Series B Preferred Stock is convertible into 0.6465903 of a share of Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The shares have no expiration date.
- TLS Beta Pte. Ltd. is a wholly-owned subsidiary of Temasek Life Sciences Private Limited, which in turn is a wholly-owned subsidiary of Fullerton Management Pte Ltd, which in turn is a wholly-owned subsidiary of Temasek Holdings (Private) Limited.

**Remarks:**

[TEMASEK HOLDINGS \(PRIVATE\) LIMITED. By: /s/ Christina Choo in her capacity as Authorised Signatory of Temasek Holdings \(Private\) Limited 05/05/2016](#)  
[FULLERTON MANAGEMENT PTE LTD. By: /s/ Cheong Kok Tim in his capacity as Director of Fullerton Management Pte Ltd 05/05/2016](#)  
[TEMASEK LIFE SCIENCES PRIVATE LIMITED. By: /s/ Lim Siew Lee Sherlyn in her capacity as Director of Temasek Life Sciences Private Limited 05/05/2016](#)  
[TLS BETA PTE. LTD. By: /s/ Christina Choo in her capacity as Director of TLS Beta Pte. Ltd. 05/05/2016](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**